Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: Vertex Pharmaceuticals Incorporated

Market Cap 115B 99.94B 92.56B 86.65B 163B 10,816B 163B 1,098B 426B 5,324B 430B 421B 18,485B P/E 2026 *
25.8x
P/E 2027 * 22.9x
Enterprise Value 102B 88.8B 82.24B 76.99B 144B 9,610B 145B 976B 378B 4,730B 382B 374B 16,424B EV / Sales 2026 *
7.81x
EV / Sales 2027 * 6.83x
Free-Float
99.8%
Yield 2026 *
-
Yield 2027 * -
Jun. 17 Vertex Pharmaceuticals Insider Sold Shares Worth $1,827,900, According to a Recent SEC Filing MT
Jun. 11 Vertex's Late-Stage Clinical Data of Casgevy Deliver Crisis-Free, Transfusion-Free Results in Kids With Blood Disorders MT
Jun. 11 Vertex Pharmaceuticals Incorporated Presents New Data on Casgevy and Announces Additional Global Regulatory Submissions CI
Jun. 10 Vertex Pharmaceuticals Incorporated Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-10-2026 11:20 AM
Jun. 09 Vertex Pharmaceuticals Insider Sold Shares Worth $785,250, According to a Recent SEC Filing MT
Jun. 05 Vertex Pharmaceuticals Incorporated Presents New Data On ALYFTREK And TRIKAFTA At European Cystic Fibrosis Conference CI
Jun. 05 Worldwide Healthcare Trust outperforms benchmark; praises AstraZeneca AN
Jun. 04 Otsuka says kidney disease drug preserves function in late-stage study RE
Jun. 02 Vertex Pharmaceuticals Insider Sold Shares Worth $888,300, According to a Recent SEC Filing MT
Jun. 01 Vertex announces US FDA acceptance of biologics license application for accelerated approval of povetacicept in IgA nephropathy RE
Jun. 01 Vertex Pharmaceuticals Incorporated Announces US FDA Acceptance of Biologics License Application for Accelerated Approval of Povetacicept in IgA Nephropathy CI
May. 29 Vertex Pharmaceuticals Incorporated Presents at Bernstein 42nd Annual Strategic Decisions Conference, May-29-2026 09:00 AM
May. 21 Vertex Pharmaceuticals Says New Pain Management Drug Is Under Review at Health Canada DJ
1 day-1.60%
1 week+1.51%
Current month+0.91%
1 month+3.99%
3 months-1.40%
6 months-1.00%
Current year-0.38%
1 week 439.5
Extreme 439.5
464.98
1 month 420.01
Extreme 420.01
464.98
Current year 412.27
Extreme 412.27
507.92
1 year 362.5
Extreme 362.5
507.92
3 years 335.82
Extreme 335.82
519.88
5 years 176.36
Extreme 176.36
519.88
10 years 71.46
Extreme 71.46
519.88
Manager TitleAgeSince
Chief Executive Officer 53 2020-03-31
Director of Finance/CFO 58 2019-04-09
Chief Tech/Sci/R&D Officer - 2021-06-30
Director TitleAgeSince
Director/Board Member 66 1997-12-31
Chairman 70 2012-04-30
Director/Board Member 57 2015-06-17
Date Insider Type Main position Quantity % Market Cap.
Jun. 14Sell

Chief Technology Officer

-4,062 0.0016%
Jun. 04Sell

Chief Technology Officer

-1,745 0.0007%
May. 31Sell

General Counsel

-828 0.0003%
Change 5-day change 1-year change 3-year change Capi.($)
-1.60%+1.51%+0.72%+29.82% 115B
-1.21%-3.04%+39.94%+145.38% 980B
-2.48%-5.18%+51.52%+39.07% 550B
-2.14%-4.94%+16.71%+56.15% 382B
+0.25%-3.09%+23.00%+15.81% 316B
+0.61%-1.69%+25.42%+13.64% 272B
+0.22%-3.10%+24.25%+30.21% 268B
+4.59%+1.98%-40.02%-45.89% 199B
-1.19%-4.95%+16.56%+47.00% 182B
-1.35%-1.46%+14.59%+56.94% 154B
Average -0.43%-2.57%+17.27%+38.81% 341.7B
Weighted average by Cap. -0.81%-3.50%+26.89%+62.56%

Financials

2026 *2027 *
Net sales 13.04B 11.37B 10.53B 9.86B 18.48B 1,230B 18.6B 125B 48.41B 606B 48.94B 47.89B 2,103B 14.27B 12.44B 11.52B 10.78B 20.23B 1,346B 20.35B 137B 52.97B 663B 53.55B 52.4B 2,301B
Net income 4.45B 3.88B 3.59B 3.36B 6.31B 420B 6.35B 42.64B 16.53B 207B 16.71B 16.35B 718B 5.05B 4.41B 4.08B 3.82B 7.16B 477B 7.21B 48.41B 18.76B 235B 18.97B 18.56B 815B
Net Debt -12.78B -11.15B -10.32B -9.66B -18.12B -1,206B -18.23B -122B -47.47B -594B -47.99B -46.96B -2,062B -17.13B -14.94B -13.84B -12.95B -24.29B -1,617B -24.44B -164B -63.61B -796B -64.32B -62.94B -2,763B
Logo Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases. Net sales are distributed geographically as follows: the United States (62.9%), Europe (28.8%) and other (8.3%).
Employees
6,400
Date Price Change Volume
26-06-18 451.63 $ -1.60% 2,993,021
26-06-17 458.99 $ +1.28% 1,524,291
26-06-16 453.17 $ +0.60% 1,486,576
26-06-15 450.46 $ +1.24% 1,482,949
26-06-12 444.92 $ -0.03% 924,189
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
33
Last Close Price
451.63USD
Average target price
548.69USD
Spread / Average Target
+21.49%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VRTX Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!